Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Chongqing Precision Biotech is the lead sponsor of 28 current clinical trials in our China register. 27 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Targeted CEA CAR-T, MC-1-50 and Invivo CAR-T. The most-studied condition is Advanced Lung Cancer.

ClinicalTrials.gov trials by status

Recruiting2796%
Not yet open14%

Trials by phase

Phase 12486%
Phase 1/2311%
Phase 214%

Clinical trials sponsored by Chongqing Precision Biotech

28 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) NCT06686524 · ClinicalTrials.gov ↗ · Dermatomyositis, Juvenile, Dermatomyositis	Phase 1	Recruiting	2024-11	China
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07331467 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1	Recruiting	2026-01	China
PIC1 Injection Therapy for Relapsed/Refractory B-NHL NCT07456371 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma	Phase 1	Recruiting	2026-03	China
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer NCT06768151 · ClinicalTrials.gov ↗ · Advanced Lung Cancer Drug: Targeted CEA CAR-T	Phase 1	Recruiting	2024-12	China
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors NCT06010862 · ClinicalTrials.gov ↗ · Gastric Cancer, Colon Cancer, Pancreas Cancer	Phase 1	Recruiting	2023-09	China
Study of CD19 CAR-T Therapy for Refractory SLE NCT07403097 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1	Recruiting	2026-02	China
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors NCT06010875 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer	Phase 1	Recruiting	2023-11	China
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer NCT06215950 · ClinicalTrials.gov ↗ · Ovarian Cancer, Cervix Cancer, Metastatic Cancer	Phase 1	Recruiting	2024-01	China
Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma NCT06903117 · ClinicalTrials.gov ↗ · Advanced Lung Cancer Drug: Targeted CEA CAR-T	Phase 1	Recruiting	2025-03	China
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors NCT06126406 · ClinicalTrials.gov ↗ · Gastric Cancer, Colon Cancer, Rectal Cancer	Phase 1	Recruiting	2023-11	China
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE NCT06892145 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Refractory Drug: MC-1-50	Phase 1	Recruiting	2025-06	China
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE NCT07318259 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase 1	Recruiting	2026-01	China
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease NCT04776330 · ClinicalTrials.gov ↗ · Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse	Phase 1/2	Recruiting	2021-03	China
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases NCT07184450 · ClinicalTrials.gov ↗ · Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc)	Phase 1	Recruiting	2025-09	China
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease NCT04271644 · ClinicalTrials.gov ↗ · Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse	Phase 1/2	Recruiting	2019-04	China
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis NCT06569472 · ClinicalTrials.gov ↗ · Juvenile Dermatomyositis	Phase 1	Recruiting	2024-07	China
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma NCT07715630 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM) Drug: Invivo CAR-T	Phase 1	Recruiting	2026-07	China
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474 · ClinicalTrials.gov ↗ · T-ALL/Lymphoma	Phase 1	Recruiting	2025-03	China
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma NCT06180174 · ClinicalTrials.gov ↗ · B Cell Lymphoma, Non Hodgkin Lymphoma Drug: MC-1-50	Phase 1	Recruiting	2023-12	China
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia	Phase 2	Recruiting	2022-01	China
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN NCT06690827 · ClinicalTrials.gov ↗ · AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)	Phase 1	Recruiting	2024-12	China
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466 · ClinicalTrials.gov ↗ · Colorectal Cancer, Esophagus Cancer, Gastric Cancer	Phase 1	Recruiting	2023-08	China
Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer NCT06992583 · ClinicalTrials.gov ↗ · Advanced Lung Cancer Drug: Targeted CEA CAR-T	Phase 1	Recruiting	2025-05	China
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors NCT07179692 · ClinicalTrials.gov ↗ · Lung Cancer, Gastric Cancer, Colon Cancer	Phase 1	Recruiting	2025-09	China
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL NCT04781634 · ClinicalTrials.gov ↗ · B-ALL	Phase 1/2	Recruiting	2021-03	China
Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer NCT06945523 · ClinicalTrials.gov ↗ · Advanced Lung Cancer Drug: Targeted CEA CAR-T	Phase 1	Recruiting	2025-04	China
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies NCT07239323 · ClinicalTrials.gov ↗ · B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma Drug: Invivo CAR-T	Phase 1	Recruiting	2025-07	China
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL NCT06641024 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Drug: MC-1-50	Phase 1	Not yet open	2024-11	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Chongqing Precision Biotech trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Targeted CEA CAR-T4 MC-1-503 Invivo CAR-T2

Conditions in Chongqing Precision Biotech trials

41 conditions

Advanced Lung Cancer4 Gastric Cancer4 Systemic Lupus Erythematosus3 Colon Cancer3 Multiple Myeloma3 Pancreas Cancer2 Esophagus Cancer2 Ovarian Cancer2Cervix Cancer2Metastatic Cancer2 Rectal Cancer2Neoplasm, Plasma Cell2Multiple Myeloma in Relapse2Refractory Acute Lymphoblastic Leukemia2Dermatomyositis, Juvenile1Dermatomyositis1Non-Hodgkin Lymphoma1 Renal Cell Carcinoma1 Advanced Cancer1 Breast Cancer1 Systemic Lupus Erythematosus (SLE)1Refractory1Juvenile Dermatomyositis (JDM)1Polyarticular Juvenile Idiopathic Arthritis1

By trial register

Register	Trials	Recruiting
Clinical trials in China	28	27

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Lung Cancer

Sponsor	Trials
Beijing Geekgene Technology	1

Sponsors with the most current trials registered for this condition.

Questions about Chongqing Precision Biotech trials

How many clinical trials does Chongqing Precision Biotech sponsor?

Chongqing Precision Biotech is the lead sponsor of 28 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chongqing Precision Biotech trials recruiting?

Yes. 27 of its 28 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chongqing Precision Biotech testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Targeted CEA CAR-T (4), MC-1-50 (3) and Invivo CAR-T (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Chongqing Precision Biotech clinical trials